At DoseEmAll, we are committed to making an impact on the lives of patients living with neurological disorders. Our purpose is helping people live longer, healthier, happier lives through discovering and developing breakthrough medicines. Notably, we lead the industry with the fastest record of getting drugs to market.
At DoseEmAll, we are creating a new paradigm for innovative health solutions. Our corporate partners have the same forward-thinking approach, and include the proven industry leaders Labraat, makers of SussStat DNA adduct test, and Glop Industries, named one of Environmental Health Perspectives "Top 50 Companies to Watch".
As a fully-integrated product development company we look for and encourage initiative in all our employees. If you enjoy a fast-paced environment not hindered by scientific reluctance to produce results, DoseEmAll is the company for you.
At DoseEmAll, we're committed to making sure every human being receives the right pharmaceutical intervention for their illness, no manner how small that illness is. From mild headaches to crippling neurological disabilities, we believe DoseEmAll products are right for you.
Recently, DoseEmAll teamed up with the Epiville General Hospital to conduct a Phase III randomized trial of the ability of our newest drug, KimFaderol, to prevent progression to the worst stage Susser Syndrome). Preliminary research is encouraging, and if the results of the randomized trial prove that KimFaderol is effective, look for our television advertisements in the near future!